| Website | atoxbio.com |
| Category | BioTech |
| Phone | 972-8-648-4111 |
| dant@atoxbio.com | |
| Employees |
| TOTAL | $3.25M |
| FUNDING TOTAL | $3.25M |
| Series A, 12/11 Esperante Ventures | $3.25M |
Atox Bio is a clinical stage biotechnology company that develops therapeutics for diseases mediated by a deregulated inflammatory response. Atox Bio focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well as ischemia/reperfusion injuries.
